This is further sustained by the observation that patients with lymph node metastases immunoreactive for fascin experienced a more aggressive clinical course than patients with negative lymph node metastases (Figure 4A). This evidence concerns the gene FSCN1 and metastatic malignant neoplasm in the lymph nodes.